Payment overview · 2025
General Payments
$539.00
30 reported records · 10 companies
Healthcare provider profile · identity verified
Scotty Dwayne Combs, APRN
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · JACKSON, KY · NPI 1730317561
Verified facts
What the public records show
CMS Open Payments records show Scotty Dwayne Combs, APRN received $539.00 in general payments during 2025 across 30 reported records.
ABBVIE INC. accounted for 30.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 15 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Rybelsus, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ARMOUR THYROID as an associated drug or biological on 50 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Armour Thyroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 85 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 80 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $166.59 | 30.9% | 8 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $94.42 | 17.5% | 5 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $53.56 | 9.9% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $49.00 | 9.1% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $46.44 | 8.6% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $43.17 | 8.0% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.10 | 7.1% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $18.81 | 3.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $15.66 | 2.9% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $13.25 | 2.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $539.00 | 30 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $141.47 | 7 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $94.42 | 5 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $86.42 | 5 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $49.00 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $46.44 | 3 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $43.17 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $43.17 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $38.10 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $33.04 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $25.12 | 1 | 2025 |
Source payment records
|
|||||
| TEZSPIRE Normalized: tezspire |
Biological | Amgen Inc. | $20.52 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $18.81 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $13.25 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 80 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 85 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | ARMOUR THYROID open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 11 recipient NPIs · example record 1201517088 |
Armour Thyroid · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
85 | 21 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
80 | 18 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Lisinopril | Lisinopril | 421 | 92 |
| Atorvastatin Calcium | Atorvastatin Calcium | 387 | 95 |
| Levothyroxine Sodium | Levothyroxine Sodium | 326 | 68 |
| Omeprazole | Omeprazole | 311 | 72 |
| Amlodipine Besylate | Amlodipine Besylate | 230 | 65 |
| Metoprolol Succinate | Metoprolol Succinate | 220 | 47 |
| Tamsulosin Hcl | Tamsulosin Hcl | 194 | 52 |
| Simvastatin | Simvastatin | 181 | 36 |
| Gabapentin | Gabapentin | 169 | 25 |
| Metformin Hcl | Metformin Hcl | 167 | 47 |
| Losartan Potassium | Losartan Potassium | 166 | 42 |
| Glipizide | Glipizide | 153 | 25 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 147 | 33 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 138 | 38 |
| Montelukast Sodium | Montelukast Sodium | 135 | 38 |
| Famotidine | Famotidine | 131 | 33 |
| Hydrochlorothiazide | Hydrochlorothiazide | 130 | 39 |
| Potassium Chloride | Potassium Chloride | 125 | 32 |
| Baclofen | Baclofen | 120 | 35 |
| Pravastatin Sodium | Pravastatin Sodium | 112 | 27 |
| Prednisone | Prednisone | 106 | 75 |
| Cefdinir | Cefdinir | 102 | 84 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 40 |
| Meloxicam | Meloxicam | 99 | 27 |
| Sertraline Hcl | Sertraline Hcl | 94 | 21 |
| Januvia | Sitagliptin Phosphate | 92 | 15 |
| Atenolol | Atenolol | 89 | 22 |
| Diclofenac Sodium | Diclofenac Sodium | 89 | 32 |
| Furosemide | Furosemide | 87 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 26 |
| Ondansetron Odt | Ondansetron | 85 | 29 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 85 | 21 |
| Jardiance | Empagliflozin | 84 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 83 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 80 | 23 |
| Ozempic | Semaglutide | 80 | 18 |
| Buspirone Hcl | Buspirone Hcl | 75 | 18 |
| Celecoxib | Celecoxib | 74 | 19 |
| Tramadol Hcl | Tramadol Hcl | 74 | 20 |
| Meclizine Hcl | Meclizine Hcl | 72 | 25 |
| Carvedilol | Carvedilol | 71 | 22 |
| Ibuprofen | Ibuprofen | 69 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 68 | 16 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 66 | 12 |
| Propranolol Hcl | Propranolol Hcl | 66 | 15 |
| Ezetimibe | Ezetimibe | 65 | 15 |
| Trazodone Hcl | Trazodone Hcl | 65 | 15 |
| Allopurinol | Allopurinol | 64 | 14 |
| Clonazepam | Clonazepam | 62 | 12 |
| Glipizide Er | Glipizide | 61 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 61 | 11 |
| Eliquis | Apixaban | 58 | 17 |
| Fenofibrate | Fenofibrate | 57 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 57 | 14 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 19 |
| Nortriptyline Hcl | Nortriptyline Hcl | 53 | 11 |
| Xarelto | Rivaroxaban | 50 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 49 | 11 |
| Tizanidine Hcl | Tizanidine Hcl | 49 | 14 |
| Promethazine Hcl | Promethazine Hcl | 48 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 47 | suppressed |
| Mirtazapine | Mirtazapine | 47 | suppressed |
| Pregabalin | Pregabalin | 45 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 42 | 14 |
| Topiramate | Topiramate | 42 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 40 | 12 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 39 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 38 | suppressed |
| Finasteride | Finasteride | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 28 |
| Alendronate Sodium | Alendronate Sodium | 35 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 34 | 15 |
| Fluconazole | Fluconazole | 34 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 34 | 25 |
| Chlorthalidone | Chlorthalidone | 32 | 12 |
| Dexlansoprazole Dr | Dexlansoprazole | 32 | suppressed |
| Alprazolam | Alprazolam | 31 | suppressed |
| Bupropion Xl | Bupropion Hcl | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 11 |
| Vascepa | Icosapent Ethyl | 30 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 29 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 29 | suppressed |
| Diazepam | Diazepam | 28 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Spironolactone | Spironolactone | 28 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 28 | 20 |
| Nifedipine Er | Nifedipine | 27 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Naproxen | Naproxen | 26 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 26 | suppressed |
| Bumetanide | Bumetanide | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 25 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 25 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 25 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Lovastatin | Lovastatin | 24 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 24 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 23 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 23 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 19 |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 22 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 21 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 21 | 20 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 21 | suppressed |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Trulicity | Dulaglutide | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 20 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 20 | suppressed |
| Lidocaine | Lidocaine | 20 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 20 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 19 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 19 | suppressed |
| Sucralfate | Sucralfate | 19 | suppressed |
| Valsartan | Valsartan | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Mounjaro | Tirzepatide | 18 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 17 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 16 | suppressed |
| Levetiracetam | Levetiracetam | 16 | suppressed |
| Novolog | Insulin Aspart | 16 | suppressed |
| Roflumilast | Roflumilast | 16 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 15 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 14 | 11 |
| Desloratadine | Desloratadine | 14 | suppressed |
| Nitroglycerin | Nitroglycerin | 14 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 14 | 14 |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 13 | suppressed |
| Armour Thyroid | Thyroid,pork | 13 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 13 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 12 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 12 | suppressed |
| Amoxicillin | Amoxicillin | 12 | 12 |
| Diclofenac Potassium | Diclofenac Potassium | 12 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 12 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 12 | 12 |
| Primidone | Primidone | 12 | suppressed |
| Belsomra | Suvorexant | 11 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 11 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 11 | suppressed |
| Entresto | Sacubitril/Valsartan | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $539.00 · 30 records | ABBVIE INC. | BREZTRI, CAPLYTA, CRYSVITA, Cologuard Collection Kit, Kerendia, OTEZLA, Ozempic, QULIPTA, REPATHA, Rybelsus, TEZSPIRE, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, VRAYLAR | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error